Clinical Trial

Trial to Evaluate Efficacy+Safety of Revita DMR Treatment Paradigm 1 and Retreatment in Type 2 Diabetes Patients

Study acronym: REMIND
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate feasibility, safety, and efficacy of endoscopic DMR Treatment Paradigm 1 (compared to sham) and to evaluate feasibility, safety, and efficacy of re-treatment with DMR at 24 weeks (compared to baseline and a single DMR procedure) in patients with type 2 diabetes with non-insulin glucose lowering medications.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-07
notable Primary completion pushed: 2027-01-01 -> 2027-03-01 2026-08-07
minor Completion pushed: 2027-07-01 -> 2028-01-01 2026-08-07
Trial Details
NCT Number NCT06092476
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Fractyl Health Inc.
Conditions Diabetes Mellitus, Type 2
Enrollment 18 participants
Start Date 2024-08-09
Primary Completion 2027-03-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06